Cadrenal Therapeutics (NASDAQ:CVKD) Stock Price Up 14.3% – Time to Buy?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was up 14.3% during trading on Wednesday . The stock traded as high as $20.63 and last traded at $19.89. Approximately 125,227 shares traded hands during mid-day trading, an increase of 114% from the average daily volume of 58,609 shares. The stock had previously closed at $17.40.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price target on Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Cadrenal Therapeutics Trading Up 14.3 %

The business’s fifty day simple moving average is $14.85. The firm has a market capitalization of $35.40 million, a price-to-earnings ratio of -2.98 and a beta of 1.26.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($2.18) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.35). On average, research analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.